HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept

Journal of Ovarian Research

Raoul Orvieto¹  Gil Yerushalmi¹  Ariel Hourvitz¹  Shir Dar¹  Ronit Machtinger¹  Alon Kedem¹  Jigal Haas¹ 

[1] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

关键词: Prevention;    hCG rescue;    GnRH agonist trigger;    Ovarian stimulation;    Ovarian hyperstimulation syndrome;   

Others  :  801730
DOI  :  10.1186/1757-2215-7-35

 received in 2014-02-24, accepted in 2014-04-01,  发布年份 2014

【 摘 要 】

Background

Controlled ovarian hyperstimulation (COH) which combining GnRH antagonist co-treatment and GnRH agonist trigger with an additional 1500 IU hCG luteal rescue on day of oocytes retrieval, has become a common tool aiming to reduce severe ovarian hyperstimulation syndrome (OHSS). In the present, proof of concept study, we evaluate whether by deferring the hCG rescue bolus for 3 days, we are still able to rescue the luteal phase.

Methods

Patients undergoing the GnRH-antagonist protocol, who were considered at high risk for developing severe OHSS and received GnRH-agonist for final oocyte maturation, were included. For luteal phase support, all patients received an “intense” luteal support. Those who had no signs of early moderate OHSS on day 3 after oocytes retrieval were instructed to inject 1500 IU of HCG bolus (hCG group). Ovarian stimulation characteristics and mid luteal progesterone levels were compared between those who received the HCG bolus and those who did not.

Results

Eleven IVF cycles were evaluated, 5 in the hCG group and 6 in the intense luteal support only group. While no in-between group differences were observed in ovarian stimulation characteristics, significantly higher mid luteal progesterone levels (>127 nmol/L vs 42.1 ± 14.5 nmol/L, respectively) and a non-significant increase in pregnancy rate (40% vs 16.6%, respectively), were observed in those who receive the hCG bolus compared to those who did not.

Conclusions

hCG luteal rescue should be offered 3 days after oocytes retrieval only to those patients with no signs of early moderate OHSS. Further studies are required to elucidate the appropriate regimen of luteal HCG administration in patients undergoing final follicular maturation with GnRH-agonist.

【 授权许可】

   
2014 Haas et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Orvieto R, Ben-Rafael Z: Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Invest 1998, 5:110-113.
• [2]Orvieto R, Ben-Rafael Z: Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 1998, 13:3306-3309.
• [3]Kol S: Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004, 81:1-5.
• [4]Orvieto R: Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005, 20:320-322.
• [5]Griesinger G, Diedrich K, Devroey P, Kolibianakis EM: GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006, 12:159-168.
• [6]Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R: Substituting HCG with GnRH agonist to trigger final follicular maturation–a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006, 13:198-201.
• [7]Kol S, Humaidan P: GnRH agonist triggering: recent developments. Reprod Biomed Online 2013, 26:226-230.
• [8]Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin- releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010, 93:847-854.
• [9]Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM: The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012, 24:134-141.
• [10]Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH: Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013, 28:2522-2528.
• [11]The Practice Committee of the American Society for Reproductive Medicine (ASRM): Ovarian hyperstimulation syndrome. Fertil Steril 2008, 90:S188-S193.
• [12]Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C: The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Fertil Steril 2008, 89:84-91.
• [13]Orvieto R: Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma. J Ovarian Res 2013, 6:77. BioMed Central Full Text
• [14]Weissman A, Loumaye E, Shoham Z: Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. Hum Reprod 1996, 11:943-949.
• [15]Hutchison JS, Zeleznik AJ: The corpus luteum of the primate menstrual cycle is capable of recovering from a transient withdrawal of pituitary gonadotropin support. Endocrinology 1985, 117:1043-1049.
• [16]Hull MG, Savage PE, Bromham DR, Ismail AA, Morris AF: The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle (“ovulation”) derived form treated and untreated conception cycles. Fertil Steril 1982, 37:355-360.
• [17]Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P: Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2013, 100:742-747.
• [18]Orvieto R: Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 2012, 24:680-681.